Safety and Efficacy of Small Particle Bronchial Artery Embolization: 12-Year Study

Overview

This 12-year retrospective study evaluates the safety and efficacy of bronchial artery embolization (BAE) using small polyvinyl alcohol (PVA) particles (150–250 µm) in patients with hemoptysis. The findings suggest that smaller particles achieve effective distal embolization with a favorable safety profile and may reduce recurrent bleeding.

Background

Bronchial artery embolization is a well-established treatment for controlling significant hemoptysis, especially in patients with limited pulmonary reserve where surgery carries high mortality. Chronic pulmonary inflammation leads to hypertrophy of bronchial and non-bronchial systemic arteries, increasing bleeding risk due to high systemic arterial pressures on fragile pulmonary vessels. Traditionally, embolic particles larger than 300 µm are recommended to minimize non-target embolization, but smaller particles may provide more distal vessel occlusion and better clinical outcomes. This study reviews outcomes using 150–250 µm PVA particles over a 12-year period at a single tertiary center.

Data Highlights

A retrospective analysis included all patients aged 16 or over undergoing BAE from 2010 to 2022 for acute massive or chronic persistent hemoptysis. Technical success was defined as embolization of all hypertrophied arteries; clinical success as cessation or significant reduction of hemoptysis without further intervention within 30 days. Patients were treated with 150–250 µm PVA particles initially, with larger particles used as needed. Major complications were those requiring treatment or causing permanent sequelae; minor complications were self-limiting.

Key Findings

• Use of 150–250 µm PVA particles allowed effective distal embolization of hypertrophied bronchial and non-bronchial systemic arteries.
• Technical success was achieved by catheterizing and embolizing all visualized abnormal vessels in the majority of cases.
• Clinical success was demonstrated by complete cessation or significant reduction of hemoptysis without need for further intervention within 30 days.
• The incidence of major complications was low, indicating a favorable safety profile for small particle embolization.
• Smaller particles may reduce the risk of recurrent or persistent hemoptysis by achieving more distal vessel occlusion compared to larger particles.

Clinical Implications

Small particle BAE using 150–250 µm PVA particles is a safe and effective option for managing hemoptysis, potentially offering improved distal embolization and reduced recurrence rates. Clinicians may consider this approach especially in patients with complex bronchial and non-bronchial systemic artery hypertrophy, balancing the benefits against the traditionally perceived risks of smaller particle use.

Conclusion

This 12-year single-center study supports the use of small particle embolization in BAE as a safe and efficacious technique that may enhance clinical outcomes by achieving more distal vessel occlusion and reducing hemoptysis recurrence.

References

1. Various Authors/Institution/2024 -- Safety and Efficacy of Small Particle Bronchial Artery Embolization: Insights from a 12-Year Single-Center Study